The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia

被引:4
|
作者
Carra, Giovanna [1 ]
Panuzzo, Cristina [1 ]
Crivellaro, Sabrina [1 ]
Morena, Deborah [2 ]
Taulli, Riccardo [2 ]
Guerrasio, Angelo [1 ]
Saglio, Giuseppe [1 ]
Morotti, Alessandro [1 ]
机构
[1] Univ Turin, San Luigi Gonzaga Univ Hosp, Sch Med, Dept Clin & Biol Sci, Regione Gonzole 10, I-10043 Turin, Italy
[2] Univ Turin, San Luigi Gonzaga Univ Hosp, Sch Med, Dept Oncol, I-10043 Turin, Italy
关键词
herpesvirus-associated ubiquitin-specific protease; p190; BCR-ABL; p53; acute lymphoblastic leukemia; herpesvirus-associated ubiquitin-specific protease inhibitors; ONCOGENE ADDICTION; CELLS; PTEN;
D O I
10.3892/ol.2016.5073
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is driven by the p190 breakpoint cluster region (BCR)-ABL isoform. Although effectively targeted by BCR-ABL tyrosine kinase inhibitors (TKIs), ALL is associated with a less effective response to TKIs compared with chronic myeloid leukemia. Therefore, the identification of additional genes required for ALL maintenance may provide possible therapeutic targets to aid the eradication of this cancer. The present study demonstrated that p190 BCR-ABL is able to interact with the deubiquitinase herpesvirus-associated ubiquitin-specific protease (HAUSP), which in turn affects p53 protein stability. Notably, the inhibition of HAUSP with small molecule inhibitors promoted the upregulation of p53 protein levels. These results suggest that HAUSP inhibitors may harbor clinically relevant implications in the treatment of Ph+ ALL.
引用
收藏
页码:3123 / 3126
页数:4
相关论文
共 46 条
  • [31] CO-EXPRESSION OF P190 AND P 210 BCR-ABL FUSION TRANSCRIPTS AND RESPONSE TO TKI THERAPY IN CHRONIC MYELOID LEUKEMIA: THE RET (RETE EMATOLOGICA TOSCANA) EXPERIENCE
    Biagiotti, C.
    Scappini, B.
    Pancani, F.
    Gozzini, A.
    Caciagli, B.
    Occhini, U.
    Birtolo, S.
    Innocenti, F.
    Ponziani, V.
    Santini, V.
    Bosi, A.
    HAEMATOLOGICA, 2013, 98 : 559 - 560
  • [32] Generation of Fas-independent CD4+cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide
    Tanaka, Y
    Takahashi, T
    Nieda, M
    Masuda, S
    Kashiwase, K
    Takahashi, T
    Ogawa, S
    Chiba, S
    Juji, T
    Hirai, H
    LEUKEMIA RESEARCH, 2002, 26 (03) : 317 - 321
  • [33] QUANTITATION OF MINIMAL RESIDUAL DISEASE BY COMPETITIVE PCR FOR P190 BCR-ABL MESSENGER-RNA IN PH-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)
    VANRHEE, F
    MARKS, DI
    FENG, L
    CROSS, NCP
    GOLDMAN, JM
    BLOOD, 1993, 82 (10) : A442 - A442
  • [34] Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (ela2)-specific CD4+ T lymphocytes
    Tanaka, Y
    Takahashi, T
    Nieda, M
    Masuda, S
    Kashiwase, K
    Ogawa, S
    Chiba, S
    Juji, T
    Hirai, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (02) : 435 - 437
  • [35] Chronic Myeloid Leukemia (CML) Patients With Atypical e1a2 P190 BCR-ABL Translocation Show a Poor Response To Therapy With Tyrosine Kinase Inhibitors (TKI)
    Montoriol-Sabate, Carme
    Martinez-Laperche, Carolina
    Jimenez-Gamiz, P.
    Collado, Rosa
    Minguela-Puras, Alfredo
    Pinan-Frances, M. A.
    Bellosillo, B.
    Martinez-Lopez, Joaquin
    Gonzalez, Marcos
    Larrayoz, Maria Jose
    Calasanz, MaJose
    Gomez-Casares, Maria Teresa
    Gonzalez-Brito, G.
    Soler, Gloria
    Roman, Jose
    Jimenez-Velasco, A.
    Buno, Ismael
    BLOOD, 2013, 122 (21)
  • [36] T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15)
    Xia, Ting
    Yang, Yuchao
    Li, Guoxia
    Chang, Jianmei
    Li, Jianlan
    Ren, Fanggang
    Ren, Weixiao
    Wang, Hongwei
    Xu, Zhifang
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (06)
  • [37] Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines
    Suh, SP
    Kee, SJ
    Lim, WH
    Song, JW
    Lee, SK
    Kim, JP
    Shin, JH
    Ryang, DW
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (09) : 939 - 944
  • [38] Acute Lymphoblastic Leukemia Expressing b3a2 (p210), e1a2 (p190), and Variant e1a2 BCR-ABL Transcripts: A Case Report and Review of the Literature
    Tan, Yanhong
    Chen, Xiuhua
    Qi, Xiling
    Li, Guoxia
    Wang, Jingjing
    Bian, Sicheng
    Xu, Zhifang
    Wang, Hongwei
    ACTA HAEMATOLOGICA, 2012, 128 (02) : 119 - 123
  • [39] The synthetic hest shock protein (Hsp) 90 inhibitor EC141 induces degradation of the Bcr-Abl p190 protein and apoptosis of Philadelphia chromosome (Ph)-positive acute lymphoblastic Leukemia (ALL) cells
    Ferrajoli, Alessandra
    Wang, Yongtao
    O'Brien, Susan M.
    Faderl, Stefan H.
    Harris, David M.
    Van, Quin
    Hallevi, Inbal
    Liu, Zhiming
    Koch, Patricia E.
    Sensintaffar, John
    Burrows, Francis
    Kantarjian, Hagop M.
    Keating, Michael J.
    Estrov, Zeev
    BLOOD, 2007, 110 (11) : 819A - 819A
  • [40] The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells
    Tong, Wei-Gang
    Estrov, Zeev
    Wang, Yongtao
    O'Brien, Susan
    Faderl, Stefan
    Harris, David M.
    Quin Van Pham
    Hazan-Halevy, Inbal
    Liu, Zhiming
    Koch, Patricia
    Kantarjian, Hagop
    Keating, Michael J.
    Ferrajoli, Alessandra
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1206 - 1212